A Case of Evan's Syndrome Induced by Vedolizumab.

Vedolizumab is a monoclonal antibody against the ɑ4β7 integrin receptor used for the treatment of ulcerative colitis and Crohn's disease. Clinical trials have shown vedolizumab to be a safe and highly effective therapy in treating inflammatory bowel disease. Its unique gut-specific mechanism of action has made it an attractive agent in recent years.

Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.

Background: Clostridium difficile infection (CDI) is common in patients with inflammatory bowel disease (IBD), often leading to diagnostic confusion and delays in IBD therapy escalation. This study sought to assess outcomes after CDI in IBD patients exposed to new or escalated immunosuppressive therapy.

Methods: This multicenter retrospective cohort study included IBD patients with documented CDI at 4 academic medical centers.

Recurrent deep vein thrombosis: long-term incidence and natural history.

Objective: To determine the long-term incidence, risk factors, and associated morbidity and mortality of recurrent deep vein thrombosis (DVT).

Summary Background Data: Few studies have examined the long-term natural history and impact of recurrent DVT.

Methods: We conducted a prospective observational study that followed 153 consecutive patients with an acute first episode of DVT.